Slides
Page 1
4DMedical Limited (ASX:4DX) Annual General Meeting 28 October 2026 Delivering Next- Generation Cardiopulmonary Imaging to the World Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.com
Page 2
2 This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and their activities current as of 28 October 2026 unless otherwise stated and the information remains subject to change without notice. This information is general in nature, does not purport to be complete and is subject to change without notice. Not an offer or financial product advice The Company is not licensed to provide financial product advice. This presentation is for information purposes only and doesnot constitute financial product or investment advice or a recommendation to acquire, hold or dispose of securities in 4DMedical. It has been prepared without taking into account the objectives, financial situation or needs of any particular person. This presentation is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person toengage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation. Forward-looking statements This presentation may contain forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to risks and uncertainties, many of which are beyond the Company’s control. Except as required by law, the Company undertakes no obligation to update these statements. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe anysuch restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Disclaimer 4DMedical Limited (ASX:4DX) October 2026
Page 3
3 Agenda 1. Opening & introductions 2. Chair’s address 3. CEO’s address 4. Procedural matters 5. Formal business & poll 6. Q&A & close of meeting 4DMedical Limited (ASX:4DX) October 2026
Page 4
4 Julian Sutton Executive Director & CFO (Incoming Chair) Experienced executive with specialisation in commercialisation, capital markets and strategic growth for innovative healthcare technology companies. Funds management experience via Schroders and Credit Suisse in London. Lil Bianchi Non-Executive Chair (Outgoing) & Chair of the Audit and Risk Committee Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings. Board of Directors – significant medical and commercial sector experience Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical’s core technologies. Dr Andreas Fouras PhD Managing Director and CEO John Livingston Non-Executive Director & Chair of the Remuneration and Nomination Committee Founding partner of ASX-listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings. Dr Geraldine McGinty MD Non-Executive Director Internationally recognised expert in health care strategy and imaging economics, and prominent advocate for patient-centred care. Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City. Dr Robert A. Figlin MD Non-Executive Director & Chair of the Medical Advisory Committee Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai. Prof Christine Jenkins AM Non-Executive Director Leading Australian respiratory physician and pioneering researcher transforming care for people with asthma and chronic lung diseases through groundbreaking research, innovation and clinical leadership. 4DMedical Limited (ASX:4DX) October 2026
Page 5
5 Chair’s address Lil Bianchi Non-Executive Chair (Outgoing)
Page 6
6 CEO’s address Dr Andreas Fouras PhD Managing Director & CEO
Page 7
7 4DMedical: An overview 4DMedical Limited (ASX:4DX) October 2026 CT:VQ®- the world’s first and only non-contrast lung ventilation and perfusion product Listed on the ASX in 2020 Joined the ASX200 in 2026 100+ patented technologies 9 FDA-cleared SaaS products Deep clinical, commercial and technical expertise Global brands supporting distribution 181 global team members across the Australia, the U.S. and Europe 4DMedical was founded in Melbourne in 2013 to bring breakthrough lung functional imaging technologies to patient care. The leading pulmonary & cardiothoracic imaging analysis company in the market 4DMedical is a global medical technology company, changing the outcome for patients with lung disease by revolutionising respiratory imaging through ventilation and perfusion analysis
Page 8
8 8 4DMedical Limited (ASX:4DX) Regulatory access, clinical evidence, reimbursement and geographic footprint in place. 39% SaaS sites 540 global sites 77% scans 344k across FY26 21% revenue FY26 $7.1m $278m Cash at 30 June 2026 Regulatory & reimbursement U.S. FDA clearance of CT:VQ® (Sep 2025) CMS reimbursement at US$650.50 per scan Authorised in EU, UK, Canada, NZ and Australia; paid AU contracts within days of TGA listing U.S. commercial adoption 5 leading AMCs on full commercial terms, incl. Cleveland Clinic, Stanford and UChicago SimonMed: 170-site outpatient network, no evaluation phase Philips North America distribution with CT:VQ® minimum order commitment Clinical evidence & market expansion AJRCCM: LVRS responder outcome rate improved from 46% to 76% CLEAR PE program at Mass. General supports U.S. obtainable market to US$3b AstraZeneca (Brazil) and GSK pharma contracts Global platform & capital EU presence established, contextflow acquisition; 25,000-procedure German screening contract Lung eco-system partnerships | RevealDx investment, Azra AI partnership $233m raised across two placements; S&P/ASX 200 inclusion 6 CT:VQ® markets regulatory cleared FY26: Foundations for rapid growth
Page 9
9 4DMedical Limited (ASX:4DX) October 2026 | Source: Yahoo Finance | Chart legend in alphabetical order CT:VQ® marketsU.S. Academic Medical Centres early adaptors of CT:VQ® Share price performance since 1 July 2025 Strong share price performance, including relative to ASX listed med-tech industry peers 0% 1,000% 2,000% 3,000% 4DX AYA CYC EIQ ENL M7T NAN PCK PME PNV 4DMedical FY26 YTD FY27 1,712% 0%
Page 10
10 A market-leading portfolio of pulmonary structure, function and cardiovascular imaging products delivered via a powerful, scalable SaaS platform 4DMedical Limited (ASX:4DX) October 2026 Regulatory & reimbursement Category Product FDA CMS reimbursement CE Mark TGA CMDR MHRA Medsafe ANVISA Pulmonary Function CT:VQ® (CT-based non-contrast ventilation & perfusion imaging) CT LVAS (CT-based non-contrast ventilation analysis) XV LVAS® (Dynamic ventilation analysis – fluoroscopy) LDAf (Lung Density Analysis – Functional) (Air trapping, emphysema) Pulmonary Structure ADVANCE Chest CT (Lung cancer screening) LDAi (Lung Density Analysis – Inspiration) (Emphysema, HAA, Fissures) LTA (Lung Texture Analysis) (Interstitial lung diseases (ILD) screening, Fibrosis) IQ-UIP (Idiopathic pulmonary fibrosis (IPF) screening) Submitted Cardiovascular CAC (Coronary Calcification, Heart Disease) Submitted PHA | RV/LV (Hypertension (RV/LV, MPA, Pa/Ao)) 4DMedical’s product portfolio: a complete lung health solution
Page 11
11 4DMedical Limited (ASX:4DX) October 2026 Transformational milestone: CT:VQ® FDA clearance CT:VQ® becomes the world’sfirst and only non-contrast, CT-based ventilation-perfusion imaging technology to receive FDA clearance Reimbursement for CT:VQ®from the U.S.Centers for Medicare and Medicaid Services (CMS) atUS$650.50 per scan Introduction of CT:VQ® into the U.S. market will drivelong-term growth in demand for ventilation-perfusion scans beyond the traditional nuclear VQ indications Compelling clinical validation package across multiple lung conditions 4DMedical conducted extensive clinical testing to prove that CT:VQ® produces the same diagnostic resultsas SPECT Nuclear VQ imaging, while offering significant practical advantages such as eliminating logistical challenges, radiation exposure, and the infrastructure and specialist personnel requirements of nuclear imaging Significant, scalable commercial opportunity Large addressable market: 1 million+ VQ scans performed annually in the U.S. US$1.1 billion U.S. market US$2.6 billion global market Instantly compatible with ~14,500 CT scanners in the U.S. %90 Hig her Less More 0 1 %10 Inspiration Lower Ventilation Perfusion Higher Lower Ex piration Higher CT:VQ® FDA clearance, CMS reimbursement Regulatory & reimbursement
Page 12
12 Strategy for adoption at top-tier, influential, U.S. academic medical centres and health systems 20% 80% Top 20 U.S. Hospitals Interventional Pulmonology 1 Top 20 – U.S. Hospitals * 20% 80% Active *https://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview | 1 – source on file4DMedical Limited (ASX:4DX) October 2026 U.S. commercial adoption Future opportunity CT:VQ® contracted CT:VQ®enters U.S. Outpatient Market via SimonMed agreement Three-year commercial agreement One of the largest, fastest-growing and most influential physician-led outpatient radiology groups in the U.S. 170 site network across 10 states, 300+ radiologists SimonMed will also support the development of reimbursement evidence for CT:VQ®, sharing insurance and claims data AMCs signed commercial CT:VQ® contracts within months of FDA clearance: Stanford University Cleveland Clinic University of Miami University of Chicago UC San Diego Health Others Active Future opportunity CT:VQ® early adopters
Page 13
13 4DMedical is well positioned to provide screening services – successful burn pits trial at Vanderbilt Medical Centre & research study with VA Houston 4DMedical and Philips Reseller Agreement – a commercial agreement to combine efforts to seek contract award(s) from the U.S. Office of Veterans Affairs, DoD and other non- government U.S. payers Veterans Affairs (VA) opportunity Philips opportunity Why does VA need to act? The U.S. PACT Act has appropriated US$280 billion in additional funding over ten years for affected Veterans Requires screening for Deployment Related Respiratory Disease (DRRD) in over 4 Million eligible veterans Vanderbilt ‘burn pit’ publication demonstrates XV Technology® can detect the presence of constrictive bronchiolitis or DRCB Introduction of the AIR CARE for Veterans Act – this bill directs the VA to establish a pilot program to identify respiratory disorders using FDA approved software providing ‘four-dimensional functional lung imaging’ Surgical lung biopsy methodology (not scalable) 3-day hospital stay ~$30k cost per procedure 1 in 30 severe complication rate 30k x 4m = $120 Billion 4DMedical DRCB biomarker imaging 30-minute outpatient scans ~$1,000 (CT $650 and fluoroscopy $350) Non-invasive (98% accuracy correlation to biopsy) 1k x 4m = $4 Billion Philips and Veterans Affairs opportunity Combined capabilities to build a compelling offer for ‘owning the lung’ and shared purpose 4DMedical Limited (ASX:4DX) October 2026 U.S. commercial adoption
Page 14
14 Evidence & market expansion CLEAR: expansion into acute pulmonary embolism market CT Pulmonary Angiography (CTPA) 5× the market of Nuclear VQ Nuclear VQ 4DMedical Limited (ASX:4DX) October 2026 4DMedical has launched CLEAR (Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism) CLEAR’s corestudy is a multi-centre, multinational, prospective, observational study comparing CT:VQ® head-to-head with CTPA in patients with suspected PE CLEAR creates a pathway for CT:VQ® to address the existing nuclear VQ market of approximately 1 million scans per year It also opens the materially larger, CTPA-dominated PE opportunity of approximately 5 million scans per year Together, these markets increase CT:VQ®’s obtainable market in the United States to US$3 billion Nuclear VQ 1 million scans per year Solving supply side limitations to grow market to 1.5m scans 100% market capture $750m TAM@ 99% margins CTPA 5 million scans per year 5x market of Nuclear VQ Study underway Readout in 2027 $2.5B TAM
Page 15
15 4DMedical Limited (ASX:4DX) October 2026 Major publication validates CT:VQ® for lung surgery Published in the American Journal of Respiratory and Critical Care Medicine, the world’s leading respiratory medicine journal, and presented at the ATS 2026 International Conference, the world’s largest pulmonary and respiratory medicine meeting. Study reports that integrating functional perfusion data with anatomical emphysema information from routine non-contrast CT imaging can enhance and streamline patient selection for lung volume reduction surgery (LVRS). This approach increased the proportion of patients responding to surgery from 46% to 76%. By identifying optimal candidates earlier using existing CT scans, CT:VQ® supports higher procedural success rates. Major independent multicentre trial involving U.S. veterans validates the use of 4DMedical’s imaging biomarkers Major multi-centre study published in Respiratory Research demonstrates that XV Technology® can reveal early and subtle forms of small airways disease often missed by standard tests such as spirometry and CT scans. Researchers from Vanderbilt University, Johns Hopkins, the University of Miami and Alfred Hospital in Melbourne showed that XV Technology® identifies disease-specific and severity-specific biomarker patterns in COPD and deployment-related constrictive bronchiolitis, even when conventional tests appear normal. These maps offer actionable insights to optimise patient care and may reduce the need for invasive biopsy. A leading interventional pulmonologist presented work at AABIP showing that CT:VQ® reduced workup times for patients from 7 weeks to 3 weeks. Evidence & market expansion Clinical Validation
Page 16
16 Australian commercial adoption 4DMedical Limited (ASX:4DX) October 2026 CT:VQ® cleared by theTherapeutic Goods Administration (TGA)and listed in the Australian Register of Therapeutic Goods (ARTG) Australia is uniquely positioned for rapid adoption: >74 CT scanners per million people ranks among the highest CT-utilisation markets globally second-highest reported CT scanner density worldwide This extensive CT footprint enables CT:VQ® to become one of Australia’s most accessible functional lung imaging modalities major clinic locations include 4DMedical supports National Lung Cancer Screening Program Spectrum Medical Imaging expanded its multi-year agreement with 4DMedical including low-dose CT nodule detection for the National Lung Cancer Screening Program (NLCSP). The agreement broadens Spectrum’s technology stack to include 4DMedical’s product portfolio. TGA regulatory clearance for CT:VQ® and immediate deployments via key radiology clinics Commercial agreements signed: Jones Radiology Qscan Radiology Clinics Perth Radiological Clinic Queensland Radiology Specialists Spectrum Medical Imaging Garran Medical Imaging Integral Diagnostics Commercial progress: Australia
Page 17
17 4DMedical Limited (ASX:4DX) October 2026 Acquisition of contextflow Immediate European presence in one of the world’s largest healthcare markets, with demand for advanced lung diagnostics supported by ageing populations, a high and rising burden of respiratory disease, and expanding lung cancer screening programs across the region Commencement of commercial operations, including the introduction of CT:VQ® into a new market Existing customer base and installed footprint across Europe, including established reimbursement workflows European-based team with deep regional expertise, established clinical relationships with leading institutions CE-marked product suite already deployed within the European MDR framework Significant post-acquisition European lung cancer screening deployment lead byCuragita, covering ~25,000 screening procedures across 25 German sites over three years, including Heidelberg University’sThoraxklinik E.U. & U.K. regulatory clearances for CT:VQ® create a new, significant commercial opportunity CT is the dominant diagnostic imaging modality across European healthcare systems Large addressable market: 400,000+ VQ scans performed annually in the E.U.; 40,000 in the U.K. Instantly compatible with 13,000+ CT scanners combined in the E.U. & U.K. Combined population of ~520 million European commercial progress European expansion
Page 18
18 Global patient platform FIND Mines EMR+ Imaging reports Identify patients who warrant evaluation SCREEN contextflow DeteCT Finds and Quantifies Lung Nodules NAVIGATE Routes appropriate patients into clinical pathway & coordinates follow-up/referral QUALIFY LDAi+ CAC +MSi Incidental findings for co-morbidities Risk stratification of Malignancy CT:VQ® Adds quantitative regional ventilation- perfusion to support assessment & planning PLAN TREAT INTERVENTIONAL PULMONOLOGY/ SURGEON Performs the appropriate procedure MONITOR Support longitudinal assessment and continued patient management Lung Cancer screening: Find, Understand, Act 4DMedical Limited (ASX:4DX) October 2026 Enhancing patient journey: key partnerships and investments
Page 19
19 4DMedical Limited (ASX:4DX) October 2026 Commercial contracts with Philips VA sites Deployment-related respiratory disease screening, AIR CARE, PACT act Continued delivery of CT:VQ® across Academic Medical Centres and Health Systems Continued product adoption across community and radiology networks CT:VQ® penetration across existing contextflow sites Commercial engagement with key Academic Medical Centres and Health Systems Integration of contextflow into 4DMedical, realising commercial and cost synergies Expand commercial teams across the E.U. & U.K regions Continued CT:VQ® adoption across Radiology Networks and Public Hospital (AMC) system Referrer engagement programs across respiratory, cardiology and general practice Generate evidence supporting Medicare reimbursement with an item number Upsizing operations to support rapid global product rollout CLEAR study focusing on pulmonary embolism imaging – multiplying TAM by 6x Expand on Publications such as AJRCCM (Blue Journal) L VRS paper CT:VQ® health economic studies Continued regulatory approvals across new regions Penetration across global pharma market, device companies, AI marketplaces FY27 commercialisation priorities
Page 20
20 Procedural matters
Page 21
21 Formal Business
Page 22
22 Items of Business Item 1: Financial Report, Directors’ Report and Auditors Report Item 2: Remuneration Report Item 3: Re-election of Director, Dr Geraldine McGinty Item 4: Proposed issue of Equity Securities to Non-Executive Directors Item 5: Issue of RSUs and Options to the Managing Director and CEO Item 6: Issue of Options to the Executive Director and CFO Item 7: Renewal of approval for the Incentive Plan Item 8: Approval for proposed issue of contextflow Options Item 9: Ratification of prior issue of shares Item 10: Non-Executive Directors’ Fees Item 11: Amendment to Constitution Item 12: Election of Director, Prof Christine Jenkins
Page 23
23 Formal Business Item 1: Financial Report, Directors’ Report and Auditors Report To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2026. 4DMedical Limited (ASX:4DX) October 2026
Page 24
24 Formal Business Item 2: Remuneration report To consider, and if thought fit, to pass, the following as an ordinary resolution: “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2026, is adopted.” Further Information: The Board unanimously recommends that Shareholders vote in favour of Item 2. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. In Favour Against Proxy Discretion Abstain 26,282,333 75,081,299 3,758,435 3,713,215 25% 71.42% 3.58% 4DMedical Limited (ASX:4DX) October 2026
Page 25
25 In Favour Against Proxy Discretion Abstain 169,049,756 3,493,904 3,872,206 1,134,961 95.82% 1.98% 2.19% Formal Business Item 3: Re-election of Dr Geraldine McGinty To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.3(b) of the Constitution, Listing Rule 14.4, and for all other purposes, Dr Geraldine Mc Ginty, a non- executive Director appointed on 25 September 2023 and last re-elected on 2 November 2023, retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a Director.” Further Information: The Board (excluding Dr McGinty) unanimously recommends that Shareholders vote infavour of Item 3. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 26
26 Items 4A to 4C: Proposed issue of Equity Securities to Directors Item 4A To consider, and if thought fit, to pass, the following as anordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Options to Mr John Livingston (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.” Item 4B To consider, and if thought fit, to pass, the following as anordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Restricted Stock Units toDr Robert A. Figlin (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.” Item 4C To consider, and if thought fit, to pass, the following as anordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Restricted Stock Units toDr Geraldine McGinty (or her nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.” Formal Business In Favour Against Proxy Discretion Abstain 89,126,384 12,925,869 4,034,544 2,748,485 84.01% 12.18% 3.80% In Favour Against Proxy Discretion Abstain 89,217,748 12,858,869 3,905,544 2,853,121 84.18% 12.13% 3.69% In Favour Against Proxy Discretion Abstain 88,492,141 13,487,545 4,042,949 2,812,647 83.47% 12.72% 3.81% 4DMedical Limited (ASX:4DX) October 2026
Page 27
27 Formal Business Item 5: Issue of RSUs and Options to the Managing Director and CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed issue of up to 1,697,041 RSUs and up to 945,724 Options, and potential termination benefits, to Managing Director and CEO, Dr Andreas Fouras, under the Incentive Plan and on the terms described in the Explanatory Statement.” In Favour Against Proxy Discretion Abstain 22,145,364 80,067,641 3,842,269 2,780,008 20.88% 75.50% 3.62% Further Information: The Board (other than Dr Fouras) unanimously recommends that Shareholders vote in favour of Item 5. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 28
28 Formal Business Item 6: Issue of Options to the Executive Director and CFO To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed issue of up to 4,909,708 Options, and potential termination benefits, to Executive Director and CFO, Mr Julian Sutton, under the Incentive Plan and on the terms described in the Explanatory Statement.” In Favour Against Proxy Discretion Abstain 18,091,787 84,018,086 3,834,014 2,891,395 17.08% 79.30% 3.62% Further Information: The Board (other than Mr Sutton) unanimously recommends that Shareholders vote infavour of Item 6. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 29
29 Formal Business Item 7: Renewal of approval for the Incentive Plan To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rules 7.1 and 7.2 Exception 13 and for all other purposes, the 4DMedical Long Term Incentive Plan (the key terms of which are summarised in the Explanatory Statement accompanying this Notice) and the future issues of securities unde r that plan, be approved, on the terms and conditions set out in the Explanatory Statement.” In Favour Against Proxy Discretion Abstain 34,189,520 67,783,176 3,849,851 2,802,929 32.31% 64.05% 3.64% Further Information: The Board does not make any recommendations in respect of this item 7 given their eligibility to participate in the IncentivePlan. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 30
30 In Favour Against Proxy Discretion Abstain 165,958,499 6,728,475 4,200,996 662,857 93.82% 3.80% 2.37% Formal Business Item 8: Approval for the proposed issue of the contextflow Options To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue of up to 3,76 6,252 Options on the terms and conditions set out in the Explanatory Statement.” Further Information: The Board unanimously recommends that Shareholders vote in favour of Item 8. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 31
31 Formal Business Item 9: Ratification of prior issue of shares To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 34,907,388 Sha res on the terms and conditions set out in the Explanatory Statement.” In Favour Against Proxy Discretion Abstain 94,820,694 1,524,033 4,016,312 590,001 94.48% 1.52% 4.00% Further Information: The Board unanimously recommends that Shareholders vote in favour of Item 9. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 32
32 Formal Business Item 10: Non-Executive Directors’ Fee To consider, and if thought fit, to pass, the following as an ordinary resolution: “That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to the Directors of the Company as a whole (other than Executive Directors) for the financial year from and including the year commencing 1 July 2026, be increased by $450,000 per annum from $750,000 per annum to $1,200,000 per annum on the terms and conditions set out in the Explanatory Statement.” In Favour Against Proxy Discretion Abstain 93,665,901 8,546,709 3,878,287 2,744,385 88.29% 8.06% 3.66% Further Information: The Board does not make any recommendations in respect of this item 10 as it involves payment of fees to Directors. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 33
33 In Favour Against Proxy Discretion Abstain 94,376,894 76,712,948 4,642,834 1,818,151 53.70% 43.65% 2.64% Formal Business Item 11: Amendment to Constitution To consider, and if thought fit, to pass, the following as a special resolution: That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Members of the Company approve the amendments to the Company’s Constitution by inserting a new Clause 23.6(d) to increase the issue cap to 10% for the purposes of section 1100V of the Corporations Act, as set out in the Explanatory Statement. Further Information: The Board unanimously recommends that Shareholders vote in favour of Item 11. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 34
34 Formal Business Item 12: Election of Director, Prof Christine Jenkins To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.4, and for all other purposes, Prof Christine Jenkins, a non-executive director appointed on 23 September 2026, and being eligible, is re-elected as a director.” In Favour Against Proxy Discretion Abstain 159,693,565 4,573,892 2,537,792 341,720 95.74% 2.74% 1.52% Further Information: The Board (other than Prof Jenkins) unanimously recommends that Shareholders vote infavour of Item 12. The Chair of the meeting intends to vote undirected proxies in favour of the Item. The voting exclusion for this item is as disclosed in the Notice of Meeting. 4DMedical Limited (ASX:4DX) October 2026
Page 35
35 Poll
Page 36
36 Q&A
Page 37
37 4DMedical Limited (ASX:4DX) Annual General Meeting 28 October 2026 Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831